Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Targovax ASA ( (GB:0RIS) ) has issued an announcement.
Circio Holding ASA has exercised its option under a financing agreement with Atlas to secure an additional NOK 4,000,000 through convertible bonds, ensuring operational funding until June 2025. This move strengthens Circio’s financial position, supporting its innovative RNA technology development and ongoing cancer vaccine trials, potentially enhancing its market standing and providing low-cost future opportunities.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced circular RNA vector expression technology for nucleic acid medicine. Their proprietary circVec platform enhances protein expression significantly compared to traditional mRNA systems and is used in various therapeutic applications, including genetic medicine and chronic disease. Additionally, Circio is working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,111,100
Current Market Cap: NOK63.39M
For a thorough assessment of 0RIS stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- #BoycottWalmart Gains Steam Post “No Kings” Protests, Walmart Stock (NYSE:WMT) Notches Up
- “Prices at the National Level…Stopped Falling”: iShares S&P / TSX Capped REIT Index ETF Stock (TSE:XRE) Notch Up as Home Sales Mount
- 3 “Strong Buy” Technology Stocks to Buy Now, 6/16/25, According to Top Analysts
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue